Last reviewed · How we verify
Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies
Evaluation the safety and efficacy of cord blood-derived CAR-T cells in patients with relapsed/refractory B cell leukemia/lymphoma whose disease relapsed after autologous CAR-T cells therapy or who fail to preparation for autologous CAR-T cells
Details
| Lead sponsor | Henan Cancer Hospital |
|---|---|
| Phase | PHASE1 |
| Status | UNKNOWN |
| Enrolment | 20 |
| Start date | Wed Feb 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Mon Jan 31 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Refractory
- Relapsed
- B Cell Lymphoma
- B Cell Leukemia
Interventions
- CAR-T cells
Countries
China